Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;49(6): 774-776, Dec. 2016. graf
Article
en En
| LILACS
| ID: biblio-1041383
Biblioteca responsable:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS The technique is described in detail sufficient to enable replication.CONCLUSIONS:
The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Compuestos Organometálicos
/
Leishmaniasis Cutánea
/
Meglumina
/
Antiprotozoarios
Límite:
Humans
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
MEDICINA TROPICAL
Año:
2016
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Brasil